News
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.
22d
News9Live on MSNGoogle’s AI-designed cancer drug may soon enter human trials, says DeepMind exec
Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Alphabet-owned Isomorphic Labs says its first AI-designed drug is nearly ready for human trials, targeting diseases like cancer and heart failure. Nucleus_AI 2802 Stories Tuesday July 08, 2025 , 2 ...
Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO By Sarah Jackson Andrew Brookes/Getty Images Feb 26, 2024, 1:11 PM PT ...
A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?
Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO 35,048 people played the daily Crossword recently. Can you solve it faster than ...
Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.
Isomorphic Labs aims to start clinical trials for AI-designed drugs by year-end, potentially revolutionizing drug discovery timelines. Market optimism persists under Trump 2.0, with a focus on big ...
Isomorphic Labs, the four-year-old drug discovery start-up owned by Google parent Alphabet, will have an artificial intelligence-designed drug in trials by the end of this year, says its founder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results